Business
60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis
Enrollment is tracking ahead of schedule, allowing potential acceleration of key trial milestonesMinimum enrollment to support interim analysis expected as soon as early July 2026Randomized, double-blind, placebo-controlled trial is evaluating the efficacy and safety of tafenoquine in treating humans hospitalized with babesiosis at five clinical sites in northeastern U.S. WASHINGTON, May 26, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company” or 60 Degr
About this update from 60 Degrees Pharmaceuticals, Inc.
[{"type":"image","alt":"Sixty Degrees Pharmaceuticals","displaySize":"","headline":null,"caption":"Sixty Degrees Pharmaceuticals","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":157,"url":"https://media.zenfs.com/en/globenewswire.com/6c5f734cbdeffb0ff816df4f768b5fa6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/S52w9ZLj2wSSJQ7IHCYb3A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMA--/https://media.zenfs.com/en/globenewswire.com/6c5f734cbdeffb0ff816df4f768b5fa6","width":300,"height":157},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/S52w9ZLj2wSSJQ7IHCYb3A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMA--/https://media.zenfs.com/en/globenewswire.com/6c5f734cbdeffb0ff816df4f768b5fa6","width":300,"height":157}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Enrollment is tracking ahead of schedule, allowing potential acceleration of key trial milestones","length":97,"tagName":"p"}]},{"val":[{"type":"text","content":"Minimum enrollment to support interim analysis expected as soon as early July 2026","length":82,"tagName":"p"}]},{"val":[{"type":"text","content":"Randomized, double-blind, placebo-controlled trial is evaluating the efficacy and safety of tafenoquine in treating humans hospitalized with babesiosis at five clinical sites in northeastern U.S.","length":205,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":384,"olType":false},{"type":"text","content":"WASHINGTON, May 26, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company” or 60 Degrees Pharmaceuticals), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced that the first patient of the 2026 tick season has been enrolled in the randomized, double-blind, placebo-controlled clinical trial (NCT06207370) to evaluate the efficacy and safety of tafenoquine in treating babesiosis in humans.","length":494,"tagName":"p"},{"type":"text","content":"The study, which will enroll at least 24 patients prior to an interim analysis, is being conducted at five clinical sites in the Northeastern United States. The two main endpoints of the trial (clinical symptom resolution and parasite clearance) will be subject to separate interim analyses as data become available.","length":316,"tagName":"p"},{"type":"text","content":"This patient...